Paclitaxel poliglumex

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Paclitaxel poliglumex
DrugBank Accession Number
DB13809
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Synonyms
  • Paclitaxel poliglumex
External IDs
  • CT-2103

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.
AmbroxolThe risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Ambroxol.
AmsacrineThe risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Paclitaxel poliglumex.
AnastrozoleThe risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Paclitaxel poliglumex.
Arsenic trioxideThe risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel poliglumex.
Food Interactions
Not Available

Categories

ATC Codes
L01CD03 — Paclitaxel poliglumex
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
TQ64FZ98ZN
CAS number
263351-82-2
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
Not Available
RxNav
2473230

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
3Active Not RecruitingTreatmentBrenner Tumor / Clear Cell Adenocarcinoma of the Fallopian Tubes / Endometrioid Adenocarcinoma of the Fallopian Tubes / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Mucinous Adenocarcinoma of the Fallopian Tubes / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Serous Adenocarcinoma of Ovary / Stage IIIA Fallopian Tube Cancer AJCC v7 / Stage IIIA Ovarian Cancer AJCC v6 and v7 / Stage IIIA Primary Peritoneal Cancer AJCC v7 / Stage IIIB Fallopian Tube Cancer AJCC v7 / Stage IIIB Ovarian Cancer AJCC v6 and v7 / Stage IIIB Primary Peritoneal Cancer AJCC v7 / Stage IIIC Fallopian Tube Cancer AJCC v7 / Stage IIIC Ovarian Cancer AJCC v6 and v7 / Stage IIIC Primary Peritoneal Cancer AJCC v7 / Stage IV Fallopian Tube Cancer AJCC v6 and v7 / Stage IV Ovarian Cancer AJCC v6 and v7 / Stage IV Primary Peritoneal Cancer AJCC v7 / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1somestatusstop reasonjust information to hide
3TerminatedTreatmentLung Cancer4somestatusstop reasonjust information to hide
3TerminatedTreatmentNon-Small Cell Lung Cancer (NSCLC)1somestatusstop reasonjust information to hide
3WithdrawnTreatmentNon-Small Cell Lung Cancer (NSCLC)1somestatusstop reasonjust information to hide
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer (NSCLC)1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 23, 2017 20:49 / Updated at February 21, 2021 18:54